Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Solid Tumors, Metastatic Solid Tumors
Interventions: DS3610a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, Standard of Care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Chronic Myeloid Leukemia
Interventions: RAD001, Imatinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Myeloid Malignancies, Lymphoid Malignancies
Interventions: NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001; Biological
Lead sponsor: Cristina Gasparetto; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Ketamine, Scopolamine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma Bladder, DNA Repair-Deficiency Disorders
Interventions: L-NMMA, Pembrolizumab; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions: palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 35
States / cities: San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more

Conditions: Systemic Lupus Erythematosus
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 85
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, filgrastim, cyclophosphamide, cytarabine, methylprednisolone, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 49 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions: Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more

Conditions: Longevity, GLP-1, Geroscience, Aging
Interventions: Metformin, Rapamycin, Naltrexone, Vitamin C; Drug · Dietary Supplement
Lead sponsor: AgelessRx; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV-1-infection
Interventions: Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: Healthy Participants
Interventions: AZD5462, Midazolam, Rosuvastatin, Digoxin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning
Interventions: i-STRONGER, Usual Care; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 120 Years
Enrollment: 4,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Frisco, Texas

Conditions: Soft Tissue Sarcoma
Interventions: Ascorbate; Drug
Lead sponsor: Mohammed Milhem; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more

Conditions: Psoriatic Arthritis
Interventions: AIN457 (secukinumab), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Ruxolitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

A Study of DS3610a in Participants With Advanced Solid Tumor

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Phase Ib of L-NMMA and Pembrolizumab

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome